Activation of epidermal growth factor receptor (EGFR) signaling, driven by EGFR gene amplification and point mutations such as L858R and T790M, is the most common driving factor in NSCLC, accounting for ~90% of lung cancer cases [3, 4]. This evidence concerns the gene EGFR and lung carcinoma.